Related Experiment Videos
[Arrhythmia risk in left ventricular hypertrophy]
C Perings1, M Hennersdorf, E G Vester
1Heinrich-Heine-Universität Düsseldorf, Medizinische Klinik und Poliklinik B, Klinik für Kardiologie, Pneumologie und Angiologie.
Insights
Patients with arterial hypertension have a high incidence of arrhythmias. Left ventricular hypertrophy (LVH) is a key predictor of ventricular arrhythmias, and its regression may decrease their prevalence.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Electrophysiology
Background:
- Arterial hypertension significantly increases the risk of supraventricular and ventricular arrhythmias compared to normotensive individuals.
- Left ventricular hypertrophy (LVH) is a critical predictor of ventricular arrhythmogenic risk.
- Impaired left ventricular function, enlarged ventricular volumes, and the presence of late potentials are associated with increased arrhythmia risk in hypertensive patients.
Purpose of the Study:
- To investigate the relationship between left ventricular hypertrophy (LVH) and ventricular arrhythmias in patients with arterial hypertension.
- To explore the potential of pharmacological regression of LVH in reducing the prevalence of complex arrhythmias.
Main Methods:
- Analysis of arrhythmia incidence in hypertensive versus normotensive patients.
- Identification of predictors for ventricular arrhythmogenic risk, including LVH, impaired left ventricular function, and late potentials.
- Correlation of hypertension duration, muscle mass index, and documented arrhythmias (couplets, non-sustained ventricular tachycardias) with life-threatening arrhythmias.
- Electrophysiological studies to assess ventricular vulnerability in relation to LVH.
- Observation of the effect of LVH regression on ventricular extrasystole rates.
Main Results:
- Hypertensive patients exhibit a significantly higher incidence of arrhythmias (up to 96%) compared to normotensives.
- LVH, impaired left ventricular function, and late potentials are significant predictors of ventricular arrhythmias.
- Specific criteria like Simson criteria (fQRS, RMS) appear to identify patients at risk.
- Longer hypertension duration, higher muscle mass index, and frequent ventricular ectopy correlate with life-threatening arrhythmias.
- Ventricular vulnerability in electrophysiological studies is strongly dependent on LVH, and LVH regression is associated with reduced ventricular extrasystoles.
Conclusions:
- Left ventricular hypertrophy is a major determinant of ventricular arrhythmias in arterial hypertension.
- Pharmacological regression of LVH is hypothesized to decrease the prevalence of complex arrhythmias.
- Targeting LVH may be a therapeutic strategy to mitigate arrhythmia risk in hypertensive patients.
Abstract:
The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives. Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy (LVH), impaired left ventricular function with enlarged end diastolic and end diastolic volumes as well as late potentials which in case of LVH increase from a 7% to 18% incidence. Especially the Simson criteria fQRS and RMS seem to characterize patients at risk. In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias, documented by Holter recording, are determinants of life threatening arrhythmias. In addition, an increased ventricular vulnerability in electrophysiological study significantly depends on left ventricular hypertrophy. Regression of LVH goes along with a decreased rate of ventricular extrasystoles. We therefore hypothesize that by pharmacological regression of hypertrophy the prevalence of complex arrhythmias decreases.